| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 35.44 mm | 35.44 mm | 35.44 mm | 35.44 mm | 35.44 mm | 35.44 mm |
| Cash burn (monthly) | 3.24 mm | 2.92 mm | 6.71 mm | 9.11 mm | 6.70 mm | 7.08 mm |
| Cash used (since last report) | 14.81 mm | 13.37 mm | 30.71 mm | 41.69 mm | 30.67 mm | 32.42 mm |
| Cash remaining | 20.63 mm | 22.07 mm | 4.73 mm | -6.25 mm | 4.77 mm | 3.02 mm |
| Runway (months of cash) | 6.4 | 7.6 | 0.7 | -0.7 | 0.7 | 0.4 |
| 13F holders | Current |
|---|---|
| Total holders | 20 |
| Opened positions | 5 |
| Closed positions | 39 |
| Increased positions | 0 |
| Reduced positions | 10 |
| 13F shares | Current |
|---|---|
| Total value | 2.40 bn |
| Total shares | 20.07 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Roche Finance | 11.03 mm | $6.78 mm |
| Vivo Capital VIII | 3.55 mm | $46.82 mm |
| Tang Capital Partners | 2.19 mm | $37.78 mm |
| Versant Venture Capital VI | 1.46 mm | $1.09 mm |
| Wellington Biomedical Innovation Master Investors | 1.21 mm | $14.32 mm |
| Adage Capital Management | 218.81 k | $2.14 mm |
| Vivo Capital | 141.88 k | $1.23 bn |
| Ics Opportunities Ii | 125.45 k | $1.76 mm |
| Vanguard | 63.81 k | $552.63 mm |
| Acadian Asset Management | 30.60 k | $263.00 k |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 8 Oct 24 | Hardean Achneck | Stock Option Common Stock | Grant | Acquire A | No | No | 7.32 | 75,000 | 549.00 k | 75,000 |
| 4 Sep 24 | Lawrence Blatt | Stock Option Common Stock | Grant | Acquire A | No | No | 11.74 | 33,920 | 398.22 k | 33,920 |
| 4 Sep 24 | Julian A. Symons | Stock Option Common Stock | Grant | Acquire A | No | No | 11.74 | 10,880 | 127.73 k | 10,880 |
| 4 Sep 24 | Lesley Ann Calhoun | Stock Option Common Stock | Grant | Acquire A | No | No | 11.74 | 10,880 | 127.73 k | 10,880 |
